PCR Technologies Market Competitive Strategy, Benchmarking And Demand Trend Analysis
Summary
- In 2020, Roche (Switzerland) announced FDA 510(k) clearance for the cobas BKV Test on the cobas 6800 and 8800 Systems.
- In 2020, Roche (Switzerland) that the cobas SARS-CoV-2 & Influenza A/B Test received emergency use authorization for use on the cobas 6800/8800 Systems from the FDA.
In the near future, the PCR technologies market is poised for remarkable growth as advancements in molecular biology, diagnostics, and biotechnology continue to accelerate. The ongoing refinement of polymerase chain reaction (PCR) techniques, driven by innovations in enzyme formulations, primer design, and thermal cycling instrumentation, will foster the development of faster, more sensitive, and cost-effective PCR platforms. These cutting-edge solutions will revolutionize fields such as disease detection, genetic profiling, and personalized medicine, enabling rapid and accurate identification of pathogens, genetic mutations, and biomarkers. Additionally, the integration of PCR with other technologies, such as microfluidics and point-of-care devices, will extend its applications to resource-limited settings and facilitate real-time monitoring. As the demand for precise and efficient molecular analysis rises across research, clinical, and industrial domains, the PCR technologies market is poised to play an increasingly pivotal role in shaping the future of healthcare and life sciences.
Revenue Growth Analysis:
[245 Pages Report] The global PCR technologies Market is expected to reach USD 18.3 billion by 2027 from an estimated USD 12.5 billion in 2022, at a CAGR of 8.0%.
Download PDF Brochure:
Key Factors Driving Market Growth:
The growth of this market is primarily driven by the rising incidences of target diseases and genetic disorders; continuous technological advancements in PCR technologies, the development of miniaturized portable instruments, and incorporation of robotics; increasing investments, funds, and grants for research activities; increasing use of biomarker profiling for disease diagnostics; and the successful completion of the Human Genome Project.
PCR Technologies Market
Competitive Landscape:
The competitive landscape includes the analysis of the key growth strategies adopted by major players to expand their global presence and increase their shares in the market. The key growth strategies adopted by the top players in the market include product launches and approvals, agreements, expansions, and acquisitions. Product approvals and launches were the most widely adopted growth strategies by market players in the last three years to garner a larger share of the market.
Key Players:
PCR technologies market is dominated by Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Germany), Takara Bio, Inc. (Japan). Other leading players are Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Promega Corporation (US), Eppendorf AG (Germany), and Analytik Jena AG (Germany).
THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is one of the leading players in the field of healthcare and life science research. The company possesses a robust product portfolio in the PCR segment and a strong market presence globally, with sales and distribution networks in more than 50 countries. It focuses on strengthening its position in this market by adopting various growth strategies (such as product launches & approvals, acquisitions, and partnerships). The company mainly focuses on launching new products and strategic acquisitions to strengthen its market position and expand its product portfolio with technologically advanced products. The company also focuses on research partnerships with leading organizations to strengthen its research and product development capabilities in the field of dPCR and qPCR technologies.
F. HOFFMANN-LA ROCHE LTD.
Roche Diagnostics has established itself as a key player in the PCR technologies market. Roche Diagnostics strongly invests in R&D activities to improve its existing product portfolio, as it has a strong pipeline of products for this growing market. To remain competitive in the market, the company also focuses on inorganic growth strategies such as agreements and acquisitions. These strategies enable it to expand its point-of-care molecular testing portfolio. The company’s focus on product integration, through the launch of holistic and user-friendly products, will help it to further strengthen its presence in the PCR market.
BIO-RAD LABORATORIES
Bio-Rad Laboratories is one of the leading players in the field of disease diagnostics and laboratory products. The company has a noteworthy presence in the PCR industry and a wide geographic presence in major markets (such as the US, Germany, Japan, China, India, and Brazil). Bio-Rad is involved in the development, manufacturing, and marketing of more than 5,000 reagents, apparatus, and laboratory instruments (including qPCR and dPCR products). The acquisition of RainDance Technologies in 2017 enabled Bio-Rad to strengthen its position in the dPCR market by leveraging RainDance’s droplet microfluid technology for novel product development and product portfolio expansion.
The Asia Pacific market is expected to grow at the highest CAGR during the forecast period
The global PCR technologies market is segmented into North America (comprising the US and Canada), Europe (includes Germany, France, and the UK), the Asia Pacific (includes Japan, China, India), Latin America (Brazil, Mexico), and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. However, the Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The high growth of this segment is mainly attributed to the ongoing expansion & modernization of healthcare infrastructure in emerging Asian countries, increasing number of research projects in China, India, and Japan in the fields of genomics and cancer, rising outsourcing of clinical research to Asia-based CROs by leading drug manufacturing companies, and continuous government support for genomics-based research activities in emerging Asia Pacific countries.
Get more crucial industry insights:
PCR Technologies Market worth $18.3 billion by 2027 - Exclusive Report by MarketsandMarkets™
Global PCR Technologies Market to Surpass Billion-Dollar Mark by 2027
https://www.linkedin.com/pulse/pcr-technologies-market-size-key-growth-factors-analysis-james-rogen
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.